Clinical responses. Maximum percent improvements from baseline in (A) circulating Sézary cell counts (in 13 patients with erythrodermic CTCL and Sézary cell counts at baseline) and in (B) skin scores (in 19 patients with MFs/Sézary Syndrome). Partial responders (PR) are depicted by light gray bars, SD by medium gray bars, and PD by dark gray bars. The dashed line at −50% represents the threshold for PR. (C) Clinical presentations of patients with plaques (stage IB), tumors/plaques (stage IIB), and erythrodermic MFs (stage IVA) before and during treatment with near-complete clearance of plaques, tumors, and erythroderma.